Driving CAR T-cells forward (original) (raw)

• Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138 (2013).
  Article CAS Google Scholar
• Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015).
  Article CAS PubMed Google Scholar
• Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Jensen, M. C. et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant. 16, 1245–1256 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20–e22 (2006).
  Article PubMed Google Scholar
• Till, B. G. et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261–2271 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Savoldo, B. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822–1826 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra153 (2012).
  Article Google Scholar
• Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106, 3360–3365 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Zhong, X. S., Matsushita, M., Plotkin, J., Riviere, I. & Sadelain, M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18, 413–420 (2010).
  Article CAS PubMed Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• Park, J. H. et al. Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL [abstract]. J. Clin. Oncol. 33 (Suppl.), 7010 (2015).
  Article Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• US National Library of Science. ClinicalTrials.gov [online],[online], (2015).
• Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492–500 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Turtle, C. J. et al. Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition [abstract]. J. Clin. Oncol. 33 (Suppl.), 3006 (2015).
  Article Google Scholar
• Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817–4828 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709–2720 (2012).
  PubMed PubMed Central CAS Google Scholar
• Porter, D. L. et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified t cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Presented at the 55th ASH Annual Meeting and Exposition (2014).
• Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
  Article PubMed PubMed Central Google Scholar
• Kochenderfer, J. N. et al. Anti-CD19 CAR T cells administered after low-dose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B-cell lymphoma. Blood 124, 550 (2014).
  Google Scholar
• Schuster, S. J. et al. Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas [abstract]. Blood 124 (Suppl.), 3087 (2014).
  Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Sauter, C. S. et al. Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL) [abstract]. J. Clin. Oncol. 33 (Suppl.), 8515 (2015).
  Article Google Scholar
• Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra225 (2014).
  Article CAS Google Scholar
• Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Garfall, A. L. et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N. Engl. J. Med. 373, 1040–1047 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282–1295 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• US National Library of Science. ClinicalTrials.gov[online], (2014).
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• US National Library of Science. ClinicalTrials.gov[online], (2012).
• Nitschke, L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol. Rev. 230, 128–143 (2009).
  Article CAS PubMed Google Scholar
• Dotti, G., Gottschalk, S., Savoldo, B. & Brenner, M. K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 257, 107–126 (2014).
  Article CAS PubMed Google Scholar
• Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165–1174 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Till, B. G. et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119, 3940–3950 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Wang, Y. et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin. Immunol. 155, 160–175 (2014).
  Article CAS PubMed Google Scholar
• Zhang, S. et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am. J. Pathol. 181, 1903–1910 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Al-Shawi, R., Ashton, S. V., Underwood, C. & Simons, J. P. Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev. Genes Evol. 211, 161–171 (2001).
  Article CAS PubMed Google Scholar
• Hudecek, M. et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116, 4532–4541 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Vera, J. et al. T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108, 3890–3897 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Deniger, D. C. et al. Sleeping Beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations. PLoS ONE 10, e0128151 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Ellis, T. M., Simms, P. E., Slivnick, D. J., Jack, H. M. & Fisher, R. I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J. Immunol. 151, 2380–2389 (1993).
  CAS PubMed Google Scholar
• Hombach, A. et al. An anti-CD30 chimeric receptor that mediates CD3-ζ-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res. 58, 1116–1119 (1998).
  CAS PubMed Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• Zhang, H. et al. Differential expression of syndecan-1 mediates cationic nanoparticle toxicity in undifferentiated versus differentiated normal human bronchial epithelial cells. ACS Nano 5, 2756–2769 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Guo, B. et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J. Cell. Immunother. http://dx.doi.org/10.1016/j.jocit.2014.11.001 (2015).
• Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048–2060 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Feldman, E. et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 17, 314–318 (2003).
  Article CAS PubMed Google Scholar
• Roberts, A. W. et al. A phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML [abstract]. J. Clin. Oncol. 28 (Suppl.), e13012 (2010).
  Article Google Scholar
• Mardiros, A. et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122, 3138–3148 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Shi, J. et al. Identification of CD123+ myeloid dendritic cells as an early-stage immature subset with strong tumoristatic potential. Cancer Lett. 270, 19–29 (2008).
  Article CAS PubMed Google Scholar
• Tettamanti, S. et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br. J. Haematol. 161, 389–401 (2013).
  Article CAS PubMed Google Scholar
• Sievers, E. L. et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244–3254 (2001).
  Article CAS PubMed Google Scholar
• Hoyer, J. D., Grogg, K. L., Hanson, C. A., Gamez, J. D. & Dogan, A. CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage. Am. J. Clin. Pathol. 129, 316–323 (2008).
  Article PubMed Google Scholar
• Wang, Q. S. et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther. 23, 184–191 (2015).
  Article CAS PubMed Google Scholar
• Kobayashi, K. et al. Lewis blood group-related antigen expression in normal gastric epithelium, intestinal metaplasia, gastric adenoma, and gastric carcinoma. Am. J. Gastroenterol. 88, 919–924 (1993).
  CAS PubMed Google Scholar
• Peinert, S. et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther. 17, 678–686 (2010).
  Article CAS PubMed Google Scholar
• Schuessler, M. H. et al. Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type 1, Tn and sialyl-Tn in pancreas cancer. Int. J. Cancer 47, 180–187 (1991).
  Article CAS PubMed Google Scholar
• Ritchie, D. S. et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol. Ther. 21, 2122–2129 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Chang, S. S. Overview of prostate-specific membrane antigen. Rev. Urol. 6, S13–S18 (2004).
  PubMed PubMed Central Google Scholar
• Haffner, M. C. et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum. Pathol. 40, 1754–1761 (2009).
  Article CAS PubMed Google Scholar
• Maher, J., Brentjens, R. J., Gunset, G., Riviere, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat. Biotechnol. 20, 70–75 (2002).
  Article CAS PubMed Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Slovin, S. F. et al. Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR+ T cells. J. Clin. Oncol. 30, TPS4700 (2012).
  Article Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2014).
• Junghans, R. P. et al. Abstract C13: phase I trial of anti-PSMA designer T cells in advanced prostate cancer. Cancer Res. 72, C13 (2012).
  Article Google Scholar
• Hassan, R. & Ho, M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44, 46–53 (2008).
  Article CAS PubMed Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2, 112–120 (2014).
  Article PubMed CAS Google Scholar
• Maus, M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26–31 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Mathew, S. et al. The gene for fibroblast activation protein α (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics 25, 335–337 (1995).
  Article CAS PubMed Google Scholar
• Petrausch, U. et al. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer 12, 615 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Schuberth, P. C. et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J. Transl. Med. 11, 187 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• Arteaga, C. L. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 (Suppl. 4), 31–39 (2002).
  Article CAS PubMed Google Scholar
• Feldkamp, M. M., Lala, P., Lau, N., Roncari, L. & Guha, A. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45, 1442–1453 (1999).
  Article CAS PubMed Google Scholar
• Thomas, M. Cetuximab: adverse event profile and recommendations for toxicity management. Clin. J. Oncol. Nurs. 9, 332–338 (2005).
  Article PubMed Google Scholar
• Johnson, L. A. et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med. 7, 275ra222 (2015).
  Article CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• Morgan, R. A. et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 23, 1043–1053 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Hammarstrom, S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 9, 67–81 (1999).
  Article CAS PubMed Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620–626 (2011).
  Article CAS PubMed Google Scholar
• Katz, S. C. et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin. Cancer Res. 21, 3149–3159 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Huszar, M. et al. Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum. Pathol. 37, 1000–1008 (2006).
  Article CAS PubMed Google Scholar
• Meli, M. L. et al. Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells. Int. J. Cancer 83, 401–408 (1999).
  Article CAS PubMed Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2014).
• Hong, H. et al. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J. Immunother. 37, 93–104 (2014).
  Article CAS PubMed Google Scholar
• Suzuki, M. & Cheung, N. K. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin. Ther. Targets 19, 349–362 (2015).
  Article CAS PubMed Google Scholar
• Zhang, S. et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 73, 42–49 (1997).
  Article CAS PubMed Google Scholar
• Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050–6056 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• Gargett, T. & Brown, M. P. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. Cytotherapy 17, 487–495 (2015).
  Article CAS PubMed Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Baumhoer, D. et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 129, 899–906 (2008).
  Article PubMed Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Press, M. F., Cordon-Cardo, C. & Slamon, D. J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5, 953–962 (1990).
  CAS PubMed Google Scholar
• Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).
  Article CAS PubMed Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Ahmed, N. et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33, 1688–1696 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Ahmed, N. et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol. Ther. 17, 1779–1787 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Zhao, Y. et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563–5574 (2009).
  Article PubMed CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• Debinski, W., Gibo, D. M., Hulet, S. W., Connor, J. R. & Gillespie, G. Y. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin. Cancer Res. 5, 985–990 (1999).
  CAS PubMed Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2011).
• Brown, C. E. et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21, 4062–4072 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Chinnasamy, D. et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18, 1672–1683 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Chmielewski, M., Kopecky, C., Hombach, A. A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697–5706 (2011).
  Article CAS PubMed Google Scholar
• Kerkar, S. P. et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746–4757 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133–4141 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278–2288 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Chekmasova, A. A. et al. Successful eradication of established peritoneal ovarian tumors in SCID-beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin. Cancer Res. 16, 3594–3606 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Koneru, M., O'Cearbhaill, R., Pendharkar, S., Spriggs, D. R. & Brentjens, R. J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med. 13, 102 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Yin, B. W. & Lloyd, K. O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem. 276, 27371–27375 (2001).
  Article CAS PubMed Google Scholar
• Wilkie, S. et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285, 25538–25544 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Davies, D. M. et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol. Med. 18, 565–576 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• van Schalkwyk, M. C. et al. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum. Gene Ther. Clin. Dev. 24, 134–142 (2013).
  Article CAS PubMed Google Scholar
• Zhang, J., Basher, F. & Wu, J. D. NKG2D ligands in tumor immunity: two sides of a coin. Front. Immunol. 6, 97 (2015).
  PubMed PubMed Central CAS Google Scholar
• Spear, P., Barber, A., Rynda-Apple, A. & Sentman, C. L. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol. Cell Biol. 91, 435–440 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Sentman, C. L. & Meehan, K. R. NKG2D CARs as cell therapy for cancer. Cancer J. 20, 156–159 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Zhang, T., Barber, A. & Sentman, C. L. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res. 67, 11029–11036 (2007).
  Article CAS PubMed Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
  Article PubMed CAS Google Scholar
• Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Choudhury, N. & Nakamura, Y. The importance of immunopharmacogenomics in cancer treatment: patient selection and monitoring for immune checkpoint antibodies. Cancer Sci 107, 107–115 (2015).
  Google Scholar
• John, L. B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636–5646 (2013).
  Article CAS PubMed Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2016).
• Chen, J. C., Chang, Y. W., Hong, C. C., Yu, Y. H. & Su, J. L. The role of the VEGF-C/VEGFRs axis in tumor progression and therapy. Int. J. Mol. Sci. 14, 88–107 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715–725 (1998).
  Article CAS PubMed Google Scholar
• Chinnasamy, D. et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120, 3953–3968 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).
• Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540–549 (2015).
  Article CAS PubMed Google Scholar
• Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255–1263 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Science. ClinicalTrials.gov[online], (2015).